Claims
- 1. A complex of alpha-fetoprotein (AFP) and a compound having the following formulaR—CONH—X—PO(OH)2 wherein R is independently selected from and CH3(CH2)4(CH═CH—CH2)4CH2CH2—and CH3(CH2CH═CH)6CH2CH2—and CH3(CH2CH═CH)5(CH2)3—and CH3(CH2CH═CH)3(CH2)7—and where X is independently selected from —CH2—CH2—and —CH(CO2H)—CH2—and —CH(CO2H)—CH(CH3—and —CH(CO2H)—CH2—C6H5—.
- 2. A complex comprising alpha-fetoprotein and a compound selected from the group consisting of:N-(all-trans-retinoyl)-o-phospho-2-aminoethanol, N-(13-cis-retinoyl)-o-phospho-2-aminoethanol, N-(all-trans-retinoyl)-o-phospho-L-serine, N-(13-cis-retinoyl)-o-phospho-L-serine, N-(all-trans-retinoyl)-o-phospho-L-threonine, N-(13-cis-retinoyl)-o-phospho-L-threonine, N-(all-trans-retinoyl)-o-phospho-L-tyrosine, and N-(13-cis-retinoyl)-o-phospho-L-tyrosine.
- 3. A complex comprising alpha-fetoprotein and a compound selected from the group consisting of:N-linolenoyl-o-phospho-2-aminoethanol, N-linolenoyl-o-phospho-L-serine, N-linolenoyl-o-phospho-L-threonine, and N-linolenoyl-o-phospho-L-tyrosine.
- 4. A complex comprising alpha-fetoprotein and a compound selected from the group consisting of:N-docosahexaenoyl-o-phospho-2-aminoethanol, N-docosahexaenoyl-o-phospho-L-serine, N-docosahexaenoyl-o-phospho-L-threonine, and N-docosahexaenoyl-o-phospho-L-tyrosine.
- 5. A complex comprising alpha-fetoprotein and a compound selected from the group consisting of:N-eicosapentaenoyl-o-phospho-2-aminoethanol, N-eicosapentaenoyl-o-phospho-L-serine, N-eicosapentaenoyl-o-phospho-L-threonine, and N-eicosapentaenoyl-o-phospho-L-tyrosine.
- 6. A complex comprising alpha-fetoprotein and a compound selected from the group consisting of:N-arachidonoyl-o-phospho-2-aminoethanol, N-arachidonoyl-o-phospho-L-serine, N-arachidonoyl-o-phospho-L-threonine, and N-arachidonoyl-o-phospho-L-tyrosine.
- 7. A complex according to claim 1 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is at least equal to the critical micelle concentration of said complex.
- 8. A complex according to claim 2 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is at least equal to the critical micelle concentration of said complex.
- 9. A complex according to claim 3 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is at least equal to the critical micelle concentration of said complex.
- 10. A complex according to claim 4 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is at least equal to the critical micelle concentration of said complex.
- 11. A complex according to claim 5 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is at least equal to the critical micelle concentration of said complex.
- 12. A complex according to claim 6 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is at least equal to the critical micelle concentration of said complex.
- 13. A complex according to claim 1 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is 100 to 300 moles per mole alpha-fetoprotein in said complex.
- 14. A complex according to claim 2 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is 100 to 300 moles per mole alpha-fetoprotein in said complex.
- 15. A complex according to claim 3 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is 100 to 300 moles per mole alpha-fetoprotein in said complex.
- 16. A complex according to claim 4 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is 100 to 300 moles per mole alpha-fetoprotein in said complex.
- 17. A complex according to claim 5 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is 100 to 300 moles per mole alpha-fetoprotein in said complex.
- 18. A complex according to claim 6 wherein the complex is an equilibrium reversible complex wherein the concentration of said compound is 100 to 300 moles per mole alpha-fetoprotein in said complex.
- 19. A pharmaceutical composition comprising at least one complex according to claim 1.
- 20. A pharmaceutical composition comprising at least one complex according to claim 2.
- 21. A pharmaceutical composition comprising at least one complex according to claim 3.
- 22. A pharmaceutical composition comprising at least one complex according to claim 4.
- 23. A pharmaceutical composition comprising at least one complex according to claim 5.
- 24. A pharmaceutical composition comprising at least one complex according to claim 6.
- 25. A method for the treatment of cancer comprising administering a complex according to claim 1 to a patient.
- 26. A method for the treatment of cancer comprising administering a complex according to claim 2 to a patient.
- 27. A method for the treatment of cancer comprising administering a complex according to claim 3 to a patient.
- 28. A method for the treatment of cancer comprising administering a complex according to claim 4 to a patient.
- 29. A method for the treatment of cancer comprising administering a complex according to claim 5 to a patient.
- 30. A method for the treatment of cancer comprising administering a complex according to claim 6 to a patient.
Priority Claims (2)
Number |
Date |
Country |
Kind |
9804537 |
Dec 1998 |
SE |
|
9900941 |
Mar 1999 |
SE |
|
Parent Case Info
This is a Divisional application of U.S. patent application Ser. No. 09/471,105 filed Dec. 21, 1999 now U.S. Pat. No. 6,274,747.
Non-Patent Literature Citations (3)
Entry |
Sheskin et al., “Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor”, J. Med. Chem., vol. 40, pp. 659-667 (1997). |
Barua et al., “Preparation of Retinamides by Use of Retinoyl Fluoride”, J. of Lipid Research, vol. 26, pp. 258-262 (1985). |
J. Med. Chem. 40, (1997), pp. 659-667. |